N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
Industrial Transformation Training Centres - Grant ID: IC160100027
Funder
Australian Research Council
Funding Amount
$4,340,802.00
Summary
ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. Ne ....ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. New biopharmaceuticals are expected to benefit the Australian economy and provide new therapeutic options for better health outcomes. Industry-driven research projects will also provide industry-ready graduates who can drive future growth in the sector.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
High-throughput microfluidic approach to mapping hierarchies of interactions in the gene regulation machinery. The exploration of protein-protein interactions networks is becoming an extremely active area of research in life sciences. The current project will develop new approaches to accelerate the discovery of novel interacting proteins participating in gene regulation, in order to understand how cells differentiate into different tissues and organs.
Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.
The “New” Biochemistry of Polyamines: When Metabolic Pathways Collide. Basic biochemistry and the metabolic regulation of proliferation remain as the fundamental building blocks of knowledge in cell biology that have enabled breakthrough advances in biology and medicine. Polyamines are unique and ubiquitous low-Mr amines that play vital roles in many biological processes, including proliferation, DNA/RNA synthesis, etc. This proposal will mechanistically dissect the "new" biochemistry of polyami ....The “New” Biochemistry of Polyamines: When Metabolic Pathways Collide. Basic biochemistry and the metabolic regulation of proliferation remain as the fundamental building blocks of knowledge in cell biology that have enabled breakthrough advances in biology and medicine. Polyamines are unique and ubiquitous low-Mr amines that play vital roles in many biological processes, including proliferation, DNA/RNA synthesis, etc. This proposal will mechanistically dissect the "new" biochemistry of polyamines, as we have discovered that polyamines are regulated by iron at 2-major levels, involving >10-key polyamine pathway proteins. This proposal represents first-in-field studies specifically designed to dissect mechanisms involved in this relationship. Our Central Hypothesis is that iron regulates polyamine metabolism.Read moreRead less
Single-molecule optofluidics: streamlining high-throughput engineering and analysis of proteins and protein assemblies. This project aims at creating novel technologies for high-throughput engineering and analysis of proteins with single-molecule sensitivity. The platform will considerably accelerate the generation of protein-based diagnostics, new vaccines and therapeutics; it will foster collaborations with industry putting Australia at the forefront of protein research.
ARC Centre of Excellence in Plants for Space. ARC Centre of Excellence in Plants for Space. This Centre aims to create on-demand, zero-waste, high-efficiency plants and plant products to address grand challenges in sustainability for Space and on Earth. Significant advances in plant, food, and sensory science; process and systems engineering; law and policy; and psychology are expected to deliver transformative solutions for Space habitation – and create enhanced plant-derived food and bioresour ....ARC Centre of Excellence in Plants for Space. ARC Centre of Excellence in Plants for Space. This Centre aims to create on-demand, zero-waste, high-efficiency plants and plant products to address grand challenges in sustainability for Space and on Earth. Significant advances in plant, food, and sensory science; process and systems engineering; law and policy; and psychology are expected to deliver transformative solutions for Space habitation – and create enhanced plant-derived food and bioresources to capitalise upon emergent and rapidly expanding domestic and global markets. Anticipated outcomes include industry uptake of innovative plant forms, foods, technologies, and commodities; and an ambitious education and international co-ordination agenda to position Australia as a global leader in research supporting Space habitation.Read moreRead less
Australia’s first Green Biopharm . Protein-based medicines and vaccines represent the fastest growing sector of the pharmaceutical market, but their production by Australian small and medium enterprises is prohibited by the high infrastructure and operating costs of traditional manufacturing systems. This project aims to develop advanced methods to produce protein-based medicines using a native plant. The power of this technology will be demonstrated by making a biologic anti-parasite treatment, ....Australia’s first Green Biopharm . Protein-based medicines and vaccines represent the fastest growing sector of the pharmaceutical market, but their production by Australian small and medium enterprises is prohibited by the high infrastructure and operating costs of traditional manufacturing systems. This project aims to develop advanced methods to produce protein-based medicines using a native plant. The power of this technology will be demonstrated by making a biologic anti-parasite treatment, as an alternative to outdated chemical treatments. Expected outcomes include a unique scalable technology which will support Australia's sovereign capacity to produce high-value proteins, rapidly, affordably, and at scale, and with less complexity than current plant-based systems. Read moreRead less